Mali et al.: Carboxymethyl cellulose-based hydrogel films for drug deliveryThe objective of this study was to synthesize and characterize citric acid crosslinked hydrogel films of carboxymethyl cellulose-tamarind gum for topical drug delivery. The hydrogel films were characterized by attenuated total reflectance-Fourier-transform infrared spectroscopy, solid-state 13 C-nuclear magnetic resonance spectroscopy and differential scanning calorimeter. The prepared hydrogel films were evaluated for the carboxyl content and equilibrium swelling ratio. Moxifloxacin hydrochloride was loaded into these hydrogel films and drug release was monitored in the phosphate buffer pH 7.4. Haemolysis assay was used to study biocompatibility of hydrogel films. Results of the attenuated total reflectance-Fourier-transform infrared spectroscopy, solid-state 13 C-nuclear magnetic resonance and differential scanning calorimeter confirmed the formation of citric acid-crosslinked hydrogel films. Total carboxyl content of hydrogel film was found to be increased when polymer ratio and amount of citric acid was increased. In contrast, swelling of hydrogel film was found to be decreased with increase in polymer ratio and amount of citric acid. Batch B1 showed highest drug loading with non-Fickian release mechanism. All remaining batches showed nonFickian release behavior with diffusion coefficient greater than 0.5. Results of haemolysis assay indicated that the citric acid crosslinked carboxymethyl cellulose-tamarind gum hydrogels were safe to be used in drug delivery. These results indicated that the citric acid crosslinked carboxymethyl cellulose-tamarind gum composite hydrogel film has the potential to be used in topical novel drug delivery systems.
Objective: The aim of present investigation was to prepare liquisolid compacts of high dose water insoluble drug, carbamazepine (CBZ) using novel porous carriers such as Neusilin and Fujicalin in order to improve its dissolution rate and reduce the tablet weight. Materials and Methods: Solubility of CBZ was determined in different non volatile solvents to finalise vehicle having maximum solubility. The liquid retention potential (ф) of carriers and coating material was determined and 18 different liquisolid compacts of CBZ were formulated. The prepared liquisolid compacts were evaluated and compared for thickness, diameter, weight variation, uniformity of content, hardness, friability, disintegration and in vitro dissolution. Dissolution profile of liquisolid compacts was compared with marketed tablet formulation. Results and Discussion: The solubility of CBZ in polyethylene glycol 200 was found to be greater than the other solvents. Neusilin showed higher ф value than traditional carriers. Formulated liquisolid compacts showed all physical parameters within prescribed limit. Formulation containing Neusilin-Neusilin and Neusilin-Aerosil showed no disintegration while all other formulations showed disintegration up to 180 seconds. All the formulations showed drug release above 80% at the end of 15 minutes except marketed formulation. The weight of formulations containing Neusilin and Fujicalin ranged in between 0.383-0.947g. Formulation FA3 containing Fujicalin exhibited lower mean dissolution time and higher dissolution efficiency than all other formulations including marketed tablet. Conclusion: It can be concluded from this study that novel porous carriers are superior to traditional carriers in liquisolid systems and are suitable for loading high dose drugs like CBZ.
The modified ASV protocol used in this study is more cost effective as compared to the conventional protocol, deserves prospective evaluation and may be followed at least during prime time of scarcity of ASV.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.